---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-100189"
form_type: "8-K"
ticker: null
cik: "0001267602"
company_name: "ALIMERA SCIENCES INC"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:30:41.755232+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alimera Sciences completes merger with ANI Pharmaceuticals for $5.50 per share plus CVRs

## Summary
- Merger completed on September 16, 2024; shareholders receive $5.50 per share cash and one CVR.
- CVRs tied to net revenue milestones for ILUVIEN and YUTIQ: $140M in 2026 or $160M in 2027, with contingent payments.
- Nasdaq delisting requested; company to file Form 25 and Form 15 to suspend SEC reporting obligations.
- All directors resigned; new directors from merger subsidiary appointed; existing officers retained.
- Loan agreements with SLR Investment Corp. repaid and terminated in connection with the merger.

## SEC filing metadata
- accession: 0001104659-24-100189
- form_type: 8-K
- cik: 0001267602
- company_name: ALIMERA SCIENCES INC
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/tm2424081d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-100189
- JSON: https://secwatch.observer/filing/0001104659-24-100189.json
- Plain text: https://secwatch.observer/filing/0001104659-24-100189.txt

## Key facts
- Executive change
  John Snisarenko departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Peter J. Pizzo, III departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Adam Morgan departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Michael Kaseta departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Maggie Pax departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Richard S. Eiswirth, Jr. departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Ross Demont departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- Executive change
  Erin Parsons departed as Director at ALIMERA SCIENCES INC.
  - Action: ceased to be members
  - Role: Director
  source text: each of Adam Morgan, Richard S. Eiswirth, Jr., Ross Demont, Michael Kaseta, Erin Parsons, Maggie Pax, Peter J. Pizzo, III and John Snisarenko ceased to be members of the Board of Directors of the Company (the “ Company Board ”) and ceased to be members of any committees of the Company Board on which such directors served, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm
- M&A Transactions
  ALIMERA SCIENCES INC underwent a change of control involving ANI Pharmaceuticals, Inc. for $5.50 in cash and one contingent value right per share (closed 2024-09-16).
  - Action: change of control
  - Counterparty: ANI Pharmaceuticals, Inc.
  - Consideration: $5.50 in cash and one contingent value right per share
  - Closing: 2024-09-16
  source text: or shares owned by Parent, Merger Subsidiary or any other subsidiary of Parent or the Company), was canceled and ceased to exist and was converted into the right to receive (i) $5.50 in cash, without interest (such amount, as may be adjusted in accordance with the Merger Agreement, the “ Closing Cash Consideration ”) and (ii) one contingent value right (a “
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000110465924100189/0001104659-24-100189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.